SCHEMBL6169347

SCHEMBL6169347

Cc1onc(-c2cccc(Cl)c2)c1-c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 17/20 0.73
PTGS1 P23219 5/20 0.73
MT-CO2 P00403 3/20 0.73
CA1 P00915 2/20 0.73
CA2 P00918 2/20 0.73
CA12 O43570 1/20 0.73
LMNA P02545 1/20 0.73
CA3 P07451 1/20 0.73
ADRB2 P07550 1/20 0.73
ADRB1 P08588 1/20 0.73
CYP3A4 P08684 1/20 0.73
ADORA3 P0DMS8 1/20 0.73
CHRM1 P11229 1/20 0.73
ADRA2B P18089 1/20 0.73
CA4 P22748 1/20 0.73
CA6 P23280 1/20 0.73
SLC6A2 P23975 1/20 0.73
PDE4A P27815 1/20 0.73
ADORA1 P30542 1/20 0.73
CA5A P35218 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31213504 0.89 PTGS2 (0.78) PTGS2PTGS1MT-CO2CA1CA2
SCHEMBL4888365 0.86 PTGS2 (0.78) PTGS2PTGS1MT-CO2CA1CA2
SCHEMBL4880699 0.85 PTGS2 (0.75) PTGS2PTGS1MT-CO2CA1CA2
Valdecoxib SCHEMBL3853130 0.84 PTGS2 (1.00) PTGS2PTGS1MT-CO2CA1CA2
Valdecoxib SCHEMBL3356 0.84 PTGS2 (1.00) PTGS2PTGS1MT-CO2CA1CA2
SCHEMBL6168344 0.84 PTGS2 (1.00) PTGS2PTGS1MT-CO2CA1CA2
SCHEMBL4893937 0.84 PTGS2 (0.67) PTGS2PTGS1MT-CO2CA1CA2
SCHEMBL28397844 0.84 PTGS2 (0.78) PTGS2PTGS1MT-CO2CA1CA2
Valdecoxib SCHEMBL6601157 0.83 PTGS2 (0.97) PTGS2PTGS1MT-CO2CA1CA2
Valdecoxib SCHEMBL5999213 0.83 PTGS2 (0.97) PTGS2PTGS1MT-CO2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 EP claimed
CN-1442139-A Medicinal composition for treating inflammation SEARLE & CO (US) 2003-09-17 CN claimed
CN-1107058-C Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 2003-04-30 CN claimed
EP-0809636-B1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-04 EP claimed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 EP claimed
CN-1181075-A Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 1998-05-06 CN claimed
EP-0809636-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-12-03 EP claimed
WO-1996025405-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-22 WO claimed
CN-1214790-C Medicinal composition for treating inflammation SEARLE & CO (US) 2005-08-17 CN disclosed
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 EP disclosed
CN-1442139-A Medicinal composition for treating inflammation SEARLE & CO (US) 2003-09-17 CN disclosed
CN-1107058-C Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 2003-04-30 CN disclosed
EP-0809636-B1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-04 EP disclosed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 EP disclosed
CN-1181075-A Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 1998-05-06 CN disclosed
EP-0809636-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-12-03 EP disclosed
WO-1996025405-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-22 WO disclosed